HomeCompareACER vs PLD

ACER vs PLD: Dividend Comparison 2026

ACER yields 302.98% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACER wins by $1611.83M in total portfolio value
10 years
ACER
ACER
● Live price
302.98%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1618.34M
Annual income
$981,251,733.53
Full ACER calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ACER vs PLD

📍 ACER pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACERPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACER + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACER pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACER
Annual income on $10K today (after 15% tax)
$25,753.67/yr
After 10yr DRIP, annual income (after tax)
$834,063,973.50/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, ACER beats the other by $829,596,002.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACER + PLD for your $10,000?

ACER: 50%PLD: 50%
100% PLD50/50100% ACER
Portfolio after 10yr
$812.42M
Annual income
$493,254,084.86/yr
Blended yield
60.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ACER
Analyst Ratings
1
Strong
3
Buy
4
Hold
Consensus: Hold
Altman Z
-29.9
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACER buys
0
PLD buys
0
No recent congressional trades found for ACER or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACERPLD
Forward yield302.98%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$1618.34M$6.50M
Annual income after 10y$981,251,733.53$5,256,436.18
Total dividends collected$1554.65M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: ACER vs PLD ($10,000, DRIP)

YearACER PortfolioACER Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$40,998$30,298.44$11,255$555.24+$29.7KACER
2$159,961$116,092.41$13,062$1,018.59+$146.9KACER
3$594,475$423,317.38$15,903$1,926.67+$578.6KACER
4$2,106,378$1,470,289.30$20,839$3,823.32+$2.09MACER
5$7,122,619$4,868,794.58$30,464$8,166.08+$7.09MACER
6$23,007,746$15,386,544.17$52,054$19,457.30+$22.96MACER
7$71,068,926$46,450,637.66$109,886$54,188.93+$70.96MACER
8$210,139,057$134,095,305.48$304,030$186,451.18+$209.84MACER
9$595,407,325$370,558,534.30$1,166,125$840,813.32+$594.24MACER
10$1,618,337,571$981,251,733.53$6,504,190$5,256,436.18+$1611.83MACER

ACER vs PLD: Complete Analysis 2026

ACERStock

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Full ACER Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ACER vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACER vs SCHDACER vs JEPIACER vs OACER vs KOACER vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.